New! Sign up for our free email newsletter.
Science News
from research organizations

New advances in the chronic lymphocytic leukaemia genome

February 26, 2014
Center for Genomic Regulation
The Chronic Lymphatic Leukemia (CLL) Genome Consortium moves closer to the functional study of the genome and its application for improving the treatment of the disease. Researchers can now identify functional differences in leukemia cells. Their findings provide a new classification of the disease that could, eventually, improve predictions of the best time for starting treatment.

A study led by Dr. Roderic Guigó from the Centre for Genomic Regulation in Barcelona, as part of the Chronic Lymphatic leukemia Genome Consortium, has made new advances in the study of this disease. The work, which was published (in print version) last week in the journal Genome Research, scrutinised the functional profile of the genes and mutations associated with leukemia.

The Spanish Chronic Lymphatic Leukemia Genome Consortium had previously identified the principal mutations involved in the development of the disease. However, its functional profile, the activity of these mutated genes, had not been studied. Now, the researchers have sequenced the functional part of the genome of the leukemia cells, the RNA, and several populations of healthy B lymphocytes from 98 patients.

The scientists found that there are thousands of genes that are expressed in a distinct way in leukemia cells in comparison to the healthy B lymphocytes, and that their functions are also very different. In particular, in the leukemia cells many genes are expressed relating to certain metabolic pathways that make them more active.

By observing these differences, the researchers have also clearly identified two subgroups of patients with different disease behaviour, making up one group of patients that do not need treatment for a long time, while others need it more quickly. In addition, they observed that the origin of these two subgroups could be found in the activating signals received by the leukemia cells in the lymph nodes. "Thanks to the functional study of the genome we have been able to identify two clear subgroups amongst patients and we have confirmed that the aggressiveness of the disease is different in the two groups. Understanding the molecular basis of these two subgroups will enable specific treatments to be established for each of them," says Dr. Guigó.

Story Source:

Materials provided by Center for Genomic Regulation. Note: Content may be edited for style and length.

Journal Reference:

  1. P. G. Ferreira, P. Jares, D. Rico, G. Gomez-Lopez, A. Martinez-Trillos, N. Villamor, S. Ecker, A. Gonzalez-Perez, D. G. Knowles, J. Monlong, R. Johnson, V. Quesada, S. Djebali, P. Papasaikas, M. Lopez-Guerra, D. Colomer, C. Royo, M. Cazorla, M. Pinyol, G. Clot, M. Aymerich, M. Rozman, M. Kulis, D. Tamborero, A. Gouin, J. Blanc, M. Gut, I. Gut, X. S. Puente, D. G. Pisano, J. I. Martin-Subero, N. Lopez-Bigas, A. Lopez-Guillermo, A. Valencia, C. Lopez-Otin, E. Campo, R. Guigo. Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. Genome Research, 2013; 24 (2): 212 DOI: 10.1101/gr.152132.112

Cite This Page:

Center for Genomic Regulation. "New advances in the chronic lymphocytic leukaemia genome." ScienceDaily. ScienceDaily, 26 February 2014. <>.
Center for Genomic Regulation. (2014, February 26). New advances in the chronic lymphocytic leukaemia genome. ScienceDaily. Retrieved June 21, 2024 from
Center for Genomic Regulation. "New advances in the chronic lymphocytic leukaemia genome." ScienceDaily. (accessed June 21, 2024).

Explore More

from ScienceDaily